



TITAN BIOTECH LTD.

AN ISO 9001:2008 CERTIFIED COMPANY



Corp.Off. : 303-305 Lusa Tower, Azadpur Comm. Complex, Delhi-33, India

Ph.: 011-47020100, 27677960, 27675668, 27674615 | Fax: +91-11-47619811 | CIN: L74999RJ1992PLC013387

11th November, 2016

Corporate Services Department,
Bombay Stock Exchange Limited,
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai- 400001

Dear Sir,

Sub: Adoption of Un- Audited Financial Results for the quarter and half year ended 30th September, 2016

In compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit Standalone and Consolidated Un- Audited Financial results alongwith the Limited Review Report for quarter and half year ended 30th September, 2016.

Kindly take the same on your record and oblige.

Thanking you,

Yours faithfully,
For Titan Biotech Limited

Charanjit Singh
Charanjit Singh
Company Secretary

Encl. as above

R.O. & Works: Unit I: A-902 A, RIICO Industrial Area, Phase-III, Bhiwadi-301019, Rajasthan

Unit II: E-540, Industrial Area, Chopanki, Bhiwadi-301019, Rajasthan

E-mail: marketing@titanbiotechltd.com

Website: www.titanbiotechltd.com | www.titanmedia.in

Sanjay
Director

TITAN BIOTECH LIMITED
Regd. Office : A-902 A, RICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019
Phone No. 011-47020100, Fax No. +91-11-47619811 Email : hrd@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30TH SEPTEMBER, 2016 (Rs. IN LAKHS) except for EPS


PART I	Particulars	STANDALONE						Year Ended 31.03.2016 Audited
		Quarter Ended		Half Year Ended		30.09.15 Unaudited	30.09.15 Unaudited	
		30.09.16 Unaudited	30.06.16 Unaudited	30.09.15 Unaudited	30.09.15 Unaudited			
1	INCOME FROM OPERATIONS							
	a) Net Sales / Income from Operations (net of Excise Duty and Sales tax)	1318.68	1187.66	1233.70	1233.70	2516.34	2166.94	4561.28
	b) Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Total Income from Operations (Net)	1318.68	1187.66	1233.70	1233.70	2516.34	2166.94	4561.28
2	EXPENSES							
	(a) Cost of Materials Consumed	921.73	756.51	753.61	753.61	1678.24	1345.62	2972.13
	(b) Purchase of Stock in Trade	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	(c) Changes in inventories of finished goods, work in progress and stock in trade	(40.37)	9.77	30.42	30.42	(30.60)	23.28	(40.00)
	(d) Employees Benefit Expenses	98.28	98.13	88.16	88.16	196.41	157.09	336.87
	(e) Depreciation & Amortisation Expenses	16.46	16.02	16.10	16.10	34.48	37.94	76.49
	(f) Other Expenditure (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	239.21	222.62	247.79	247.79	461.83	435.83	901.11
	Total Expenses	1235.31	1105.05	1136.28	1136.28	2340.36	1999.76	4246.60
3	Profit from Operation before Other Income, finance costs & Exceptional Items	83.37	92.61	97.42	97.42	175.98	167.18	314.68
4	Other Income	26.60	0.82	10.28	10.28	29.42	17.61	42.74
5	Profit from ordinary activities before Finance Costs & Exceptional Items	111.97	93.43	107.70	107.70	205.40	184.79	357.42
6	Finance Costs	40.71	23.54	39.26	39.26	64.25	57.32	98.67
7	Profit from Ordinary activities after Finance Costs but before Exceptional Items	71.26	69.89	68.44	68.44	141.15	127.47	258.75
8	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00	0.00
9	Profit/(+)/Loss(-) from ordinary activities before Tax (-)	71.26	69.89	68.44	68.44	141.15	127.47	258.75
10	Tax Expenses							
	(a) Provision for Taxation	11.25	23.75	23.60	23.60	35.00	43.33	77.35
	(b) Provision for Deferred Tax	2.57	0.00	4.12	4.12	2.57	4.12	9.05
	Total Tax Expenses	13.82	23.75	27.72	27.72	37.57	47.45	86.41
11	Net Profit (+)/Loss(-) from Ordinary Activities after tax	57.44	46.14	41.72	41.72	103.58	80.02	172.34
12	Extraordinary Items (net of tax expense in laos)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
13	Net Profit / Loss for the period	57.44	46.14	41.72	41.72	103.58	80.02	172.34
14	Share of Profit/ (Loss) of associates	0.00	0.00	0.00	0.00	0.00	0.00	0.00
15	Minority Interest	0.00	0.00	0.00	0.00	0.00	0.00	0.00
16	Net Profit / Loss after taxes, minority interest and share of profit / (loss) of associates	57.44	46.14	41.72	41.72	103.58	80.02	172.34
17	Paid-up Equity Share Capital (Face value of Rs. 10/- per share)	773.87	773.87	773.87	773.87	773.87	773.87	773.87
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	1375.95
19(i)	Earning Per Share (before extraordinary items) (of Rs. 10/- each) (not annualised)							
	(a) Basic	0.74	0.58	0.54	0.54	1.34	1.03	2.23
	(b) Diluted	0.74	0.58	0.54	0.54	1.34	1.03	2.23
19(ii)	Earning Per Share (after extraordinary items) (of Rs. 10/- each) (not annualised)							
	(a) Basic	0.74	0.59	0.54	0.54	1.34	1.03	2.23
	(b) Diluted	0.74	0.59	0.54	0.54	1.34	1.03	2.23

(Rs. in Lakhs)

PARTICULARS	STANDALONE	
	AS AT 30.09.16 (Unaudited)	AS AT 31.03.2016 (Audited)
A EQUITY AND LIABILITIES		
1. Shareholders fund		
(a) Share Capital	773.870	773.870
(b) Reserve and Surplus	1479.541	1375.955
Sub total- Shareholders' Fund	2253.411	2149.825
Minority Interest	0.000	0.000
2. Non-current Liabilities		
(a) Long Term borrowings	510.804	427.593
(b) Deferred Tax Liabilities(net)	51.192	45.374
(c) Other Long Term Liabilities	0.000	0.000
(d) Long Term Provisions	0.000	0.000
Sub total- Non Current Liabilities	561.996	472.967
3. Current Liabilities		
(a) Short Term borrowings	604.007	713.333
(b) Trade Payables	546.745	170.677
(c) Other Current Liabilities	114.558	232.785
(d) Short Term Provisions	35.000	147.213
Sub total - Current Liabilities	1300.310	1264.008
TOTAL EQUITY & LIABILITIES	4115.717	3886.800
B ASSETS		
1. Non Current Assets		
(a) Fixed Assets	1005.305	1023.635
(b) Capital Work in Progress	566.602	451.834
(c) Non Current Investments	127.494	127.494
(d) Long term Loans and Advance	31.807	44.806
(e) Other non-current assets	0.000	0.000
Sub total Non-Current Assets	1731.208	1647.769
2. Current Assets		
(a) Inventories	1138.942	1093.826
(b) Trade Receivables	739.087	574.971
(c) Cash and Cash Equivalents	143.583	250.651
(d) Short-Term Loan and Advances	115.275	121.597
(e) Other Current Assets	247.622	197.966
Sub total - Current Assets	2384.509	2239.031
TOTAL ASSETS	4115.717	3886.800

Notes:

- The Board of Directors have approved the above Standalone Financial Results at their meeting held on 11th November, 2016 after reviewed by the Audit Committee of the Company.
- The Statutory Auditors of the Company have reviewed these Standalone Financial Results in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), 2015. There are no qualification in the Review Report issued by Statutory Auditors.
- With effect from 1st April 2015 the depreciation has been calculated on the basis of useful life of Assets.
- Previous period figures are regrouped/reclassified in line with the current period.
- The Company has only one reportable business segment.



For and on behalf of the Board
for TITAN BIOTECH LIMITED

Suresh Chand Singla
Managing Director
DIN-00027706

Place : Delhi
Dated : 11.11.2016

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30TH SEPTEMBER, 2016

S.NO.	Particulars	STANDALONE						Year Ended 31.03.2016
		Quarter Ended		Half Year Ended		Year Ended		
		30.09.15 Unaudited	30.09.16 Unaudited	30.09.15 Unaudited	30.09.16 Unaudited		30.09.15 Unaudited	
1	Total Income from Operation (Net)							
2	Net Profit (+)/Loss(-) from Ordinary Activities after tax	1318.68	1197.66	1233.70	2516.34	2166.94	4581.28	
3	Paid-up Equity Share Capital (Face value of Rs. 10/- per share)	57.44	46.14	41.72	103.58	80.02	172.34	
4	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	773.87	773.87	773.87	773.87	773.87	773.87	
5	Earning Per Share (before extraordinary items) (of Rs 10/- each) (not annualised)	N.A.	N.A.	N.A.	N.A.	N.A.	1375.95	
	(a) Basic	0.74	0.58	0.54	1.34	1.03	2.23	
	(b) Diluted	0.74	0.58	0.54	1.34	1.03	2.23	

NOTES :

The above is an extract of the detailed format of Standalone Financial Results for the Quarter & Half Year ended 30th September, 2016 filed with the BSE Limited Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Standalone Financial Results for the said Quarter & Half Year ended 30.09.2016 are available on the website of BSE Limited at www.bseindia.com and on company website at www.titanbiotech.com.



For and on behalf of the Board
for TITAN BIOTECH LIMITED

SURESH CHAND SINGLA
Managing Director
DIN-00027706

Place : Delhi
Dated : 11.11.2016

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30TH SEP. 2016 (Rs. IN LAKHS) except for EPS

PART I	Particulars	CONSOLIDATED					
		Quarter Ended		Half Year Ended		Year Ended	
		30.09.16 Unaudited	30.06.16 Unaudited	30.09.16 Unaudited	30.09.16 Unaudited	31.03.2016 Audited	
1	INCOME FROM OPERATION						
	a) Net Sales / Income from Operation (net of Excise Duty and Sales tax)	1332.78	1200.10	2532.88	4577.05		
	b) Other Operating Income	0.00	0.00	0.00	0.00		
	Total Income from Operation (Net)	1332.78	1200.10	2532.88	4577.05		
2	EXPENSES						
	(a) Cost of Materials Consumed	935.78	757.71	1693.49	2976.88		
	(b) Purchase of stock in trade	0.00	0.00	0.00	0.00		
	(c) Changes in inventories of finished goods, work in progress and stock in trade	-40.37	9.77	-30.60	-40.00		
	(d) Employees benefit Expenses	98.99	98.57	197.56	345.17		
	(e) Depreciation & Amortisation Expenses	16.94	18.49	35.43	77.07		
	(f) Other Expenditure (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	241.31	225.05	466.36	908.88		
	Total Expenses	1252.65	1109.59	2362.24	4288.00		
3	Profit from Operation before Other Income, finance costs & Exceptional Items	80.13	90.51	170.64	309.05		
4	Other Income	30.48	33.08	2.60	54.79		
5	Profit from ordinary activities before Finance Costs & Exceptional Items	110.61	83.11	203.72	363.84		
6	Finance Costs	40.72	23.54	64.26	98.72		
7	Profit from Ordinary activities after Finance Costs but before Exceptional Items	69.89	69.57	139.46	265.12		
8	Exceptional Items	0.00	0.00	0.00	0.00		
9	Profit/(+)/Loss(-) from ordinary activities before Tax (-)	69.89	69.57	139.46	265.12		
10	Tax Expenses						
	(a) Provision for Taxation	11.25	23.75	35.00	78.57		
	(b) Provision for Deferred Tax	3.11	0.00	3.11	9.73		
	Total Tax Expenses	14.36	23.75	38.11	88.30		
11	Net Profit (+)/Loss(-) from Ordinary Activities after tax	55.53	45.82	101.35	176.82		
12	Extraordinary Items (net of tax expense in secs)	0.00	0.00	0.00	0.00		
13	Net Profit / Loss for the period	55.53	45.82	101.35	176.82		
14	Share of Profit/(Loss) of associates	0.00	0.00	0.00	0.00		
15	Minority Interest	0.00	0.00	0.00	0.00		
16	Net Profit / Loss after taxes, minority interest and share of profit / (loss) of associates	55.53	45.82	101.35	176.82		
17	Paid-up Equity Share Capital (Face value of Rs. 10/- per share)	773.87	773.87	773.87	773.87		
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	N.A.	N.A.	N.A.	1379.01		
19(i)	Earning Per Share (before extraordinary items) (of Rs.10/- each) (not annualised)						
	(a) Basic	0.72	0.59	1.31	2.28		
	(b) Diluted	0.72	0.59	1.31	2.28		
19(ii)	Earning Per Share (after extraordinary items) (of Rs. 10/- each) (not annualised)						
	(a) Basic	0.72	0.59	1.31	2.28		
	(b) Diluted	0.72	0.59	1.31	2.28		

For Titan Biotech Limited

Director

PARTICULARS	CONSOLIDATED	
	AS AT 30.09.16 (Unaudited)	AS AT 31.03.2016 (Audited)
A EQUITY AND LIABILITIES		
1. Shareholders fund		
(a) Share Capital	773.870	773.870
(b) Reserve and Surplus	1477.118	1379.013
Sub total - Shareholders' Fund	2250.988	2152.883
Minority Interest	112.506	112.506
2. Non-current Liabilities		
(a) Long Term borrowings	510.604	427.593
(b) Deferred Tax Liabilities(net)	52.424	46.081
(c) Other Long Term Liabilities	0.000	0.000
(d) Long Term Provisions	0.000	0.000
Sub total- Non Current Liabilities	563.228	473.654
3. Current Liabilities		
(a) Short Term borrowings	604.007	713.333
(b) Trade Payables	564.037	170.677
(c) Other Current Liabilities	115.916	233.965
(d) Short Term Provisions	35.000	148.428
Sub total - Current Liabilities	1318.960	1266.403
TOTAL EQUITY & LIABILITIES	4245.682	4005.446
B ASSETS		
1. Non Current Assets		
(a) Fixed Assets	1109.450	1126.751
(b) Cap. Work in progress	569.359	454.573
(c) Non Current Investments	0.000	0.000
(d) Long term Loans and Advance	41.807	44.806
(e) Other non-current assets	0.500	1.000
Sub total Non-Current Assets	1721.115	1627.130
2. Current Assets		
(a) Inventories	1146.500	1098.770
(b) Trade Receivables	739.177	591.869
(c) Cash and cash equivalents	260.965	356.417
(d) Short-Term Loan and Advances	117.686	124.081
(e) Other Current Assets	260.239	207.179
Sub total - Current Assets	2524.567	2376.316
TOTAL ASSETS	4245.682	4005.446

Notes:

- The Board of Directors have approved the above Consolidated Financial Results at their meeting held on 11th November, 2016 after reviewed by the Audit Committee of the Company.
- The Statutory Auditors of the Company have reviewed the Consolidated Financial Results in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. There are no qualification in the Review Report issued by the Statutory Auditors.
- The Consolidated Financial Results for the Quarter & Half Year ended 30th September, 2016 include the results of following:-
SUBSIDIARY COMPANY - PEPTECH BIOSCIENCES LIMITED
- With effect from 1st April 2015 the depreciation has been calculated on the basis of useful life of Assets.
- Previous period figures are regrouped / reclassified in line with the current period.
- The Company has only one reportable business segment.



For and on behalf of the Board
for TITAN BIOTECH LIMITED

SURESH CHAND SINGLA
Managing Director
DIN-00027706

Place : Delhi
Dated : 11.11.2016

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30.09.2016
 (Rs. IN LAKHS) except for EPS

S.NO.	Particulars	CONSOLIDATED			
		Quarter Ended 30.09.16 Unaudited	Half Year Ended 30.09.16 Unaudited	Year Ended 31.03.2016 Audited	
1	Total Income from Operation (Net)				
2	Net Profit (+)/Loss (-) from Ordinary Activities after tax	1332.78	2532.88	4577.05	
3	Paid-up Equity Share Capital (Face value of Rs. 10/- per share)	55.53	101.35	176.82	
4	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	773.87	773.87	773.87	
5	Earning Per Share (before extraordinary items) (of Rs. 10/- each) (not annualised)	N.A.	N.A.	1379.01	
	(a) Basic	0.72	0.59	1.31	
	(b) Diluted	0.72	0.59	1.31	

NOTES :
 The above is an extract of the detailed format of Consolidated Financial Results for the Quarter & Half Year ended 30th September, 2016 filed with the BSE Limited Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Consolidated Financial Results for the Quarter & Half Year ended 30.09.2016 are available on the website of BSE Limited at www.bseindia.com and on company website at www.titanbiotech.com.



For and on behalf of the Board
 for TITAN BIOTECH LIMITED
 SURESH CHAND SINGH
 Managing Director
 DIN-00027705

Place : Delhi
 Dated : 11.11.2016




Independent Auditors' Review Report on Review of Interim Financial Results

To the Board of Directors of TITAN BIOTECH LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **TITAN BIOTECH LIMITED** ("the Holding Company") and its subsidiary (the Holding Company and its subsidiary together referred to as "the Group") for the Quarter and Half Year ended **30th September, 2016** ("the Statement") being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. CIR/CFD/CMD/15/2015 dated 30th November, 2015 and SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016. This Statement, which is the responsibility of the Holding Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Results (AS 25) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Holding Company personnel and analytical procedures applied to group financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. The Statement includes results of the subsidiary Company: Peptech Biosciences Limited
4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Sunita Agrawal & Co
Chartered Accountants

FRN: 515225C


(CA Sunita Agrawal)

FCA Partner

M.No.095196

Delhi, 11th November, 2016



Independent Auditors' Review Report on Review of Interim Financial Results


To the Board of Directors of TITAN BIOTECH LIMITED

We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **TITAN BIOTECH LIMITED** for the Quarter and Half Year ended **30th September, 2016**. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of standalone unaudited financial results prepared in accordance with the applicable Accounting Standards and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Sunita Agrawal & Co
Chartered Accountants
FRN: 515225C


(CA Sunita Agrawal)
FCA Partner
M.No.095196

Delhi, 11th November, 2016